MHRT

Summary

MHRT (myosin heavy chain associated RNA transcript, HGNC:51291) is a long non-coding RNA gene on chromosome 14q11.2.

This gene encodes a spliced long non-coding RNA that may act as a cardioprotective agent in the heart. Based on a study of a similar gene in mouse, the encoded transcript may regulate chromatin remodeling by acting as a decoy to the BRG1 chromatin repressor complex thus preventing it from binding to its genomic targets. Blocking the actions of BRG1 could be crucial in protecting the heart from pathological hypertrophy.

Source: NCBI Gene 104564225 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 445 total — 2 pathogenic, 5 likely-pathogenic (top 7% of genes corpus-wide)
• Notable: 445 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:51291
Approved symbol	MHRT
Name	myosin heavy chain associated RNA transcript
Location	14q11.2
Locus type	RNA, long non-coding
Status	Approved
Aliases	Myheart
OMIM	616096
Entrez	104564225
RNAcentral	URS00007E4CE3 — lncRNA, 876 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 0

RefSeq mRNA: 0

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 5)

• Long noncoding Mhrt RNA: molecular crowbar unravel insights into heart failure treatment (PMID:25691692)
• elevation of circulating NRON and MHRT predicts heart failure (HF) and may be considered as novel biomarkers of HF. (PMID:28296001)
• lncRNAs MHRT, FENDRR and CARMEN show distinct expression profiles in hypertensive patients (PMID:29917257)
• MHRT was ectopically expressed in gastric cancer tissues and cell lines. MHRT inhibits apoptosis and promotes proliferation and invasion of gastric cancer cells in vitro. MHRT inhibition of apoposis occurs via regulation of the expression of miR-4529-5p which then regulates expression of ROCK2. (PMID:31273599)
• Association of long-chain non-coding RNA MHRT gene single nucleotide polymorphism with risk and prognosis of chronic heart failure. (PMID:32702806)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

No reviewed (Swiss-Prot) UniProt entry for this gene.

RefSeq proteins (0): (*=MANE)

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

MSigDB gene sets: 0 (showing top):

ncRNA interactions

Experimentally supported non-coding-RNA interaction partners (NPInter).

1 interaction partners:

Partner	Partner type	Level	Source
miR-3185	miRNA	RNA-RNA	Literature mining

Disease & clinical

Genetic variants

Variant evidence for MHRT: 445 ClinVar records (7 pathogenic / likely pathogenic). Per-variant detail is on Sugi Variant.

ClinVar

445 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	5
Uncertain significance	240
Likely benign	131
Benign	19

Top pathogenic / likely-pathogenic (7)

Showing all 7 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
2780272	NM_000257.4(MYH7):c.4598T>C (p.Leu1533Pro)	Pathogenic	criteria provided, single submitter	1
835759	NM_000257.4(MYH7):c.4301G>C (p.Arg1434Pro)	Likely pathogenic	criteria provided, single submitter	1
1008293	NM_000257.4(MYH7):c.4300C>G (p.Arg1434Gly)	Likely pathogenic	criteria provided, single submitter	1
1393211	NM_000257.4(MYH7):c.4520-2del	Likely pathogenic	criteria provided, single submitter	1
2155573	NM_000257.4(MYH7):c.4486G>A (p.Glu1496Lys)	Likely pathogenic	criteria provided, single submitter	1
3242432	NM_000257.4(MYH7):c.4943del (p.Ser1648fs)	Likely pathogenic	criteria provided, single submitter	1
143209	NM_000257.4(MYH7):c.4442T>C (p.Leu1481Pro)	Pathogenic	no assertion criteria provided	1

Per-variant reference — Sugi Variant

Explore MHRT’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

Disease associations

OMIM: gene MIM:616096 | disease phenotypes: MIM:160500, MIM:181430, MIM:608358, MIM:192600, MIM:255160, MIM:613426

GenCC curated gene-disease

Mondo (9): hypertrophic cardiomyopathy (MONDO:0005045), MYH7-related skeletal myopathy (MONDO:0008050), cardiomyopathy (MONDO:0004994), dilated cardiomyopathy (MONDO:0005021), congenital myopathy 7A, myosin storage, autosomal dominant (MONDO:0008409), hypertrophic cardiomyopathy 1 (MONDO:0008647), myopathy, myosin storage, autosomal recessive (MONDO:0009708), congenital fiber-type disproportion myopathy (MONDO:0009711), dilated cardiomyopathy 1S (MONDO:0013262)

Orphanet (10): Rare hypertrophic cardiomyopathy (Orphanet:217569), Laing distal myopathy (Orphanet:59135), Familial isolated dilated cardiomyopathy (Orphanet:154), Rare cardiomyopathy (Orphanet:167848), Congenital fiber-type disproportion myopathy (Orphanet:2020), Dilated cardiomyopathy (Orphanet:217604), OBSOLETE: MYH7-related late-onset scapuloperoneal muscular dystrophy (Orphanet:437572), Left ventricular noncompaction (Orphanet:54260), Autosomal dominant myosin storage myopathy (Orphanet:636965), Autosomal recessive myosin storage myopathy (Orphanet:636970)

MeSH disease descriptors

5 disease descriptors:

Descriptor	Name	Tree numbers
D009202	Cardiomyopathies	C14.280.238
D002311	Cardiomyopathy, Dilated	C14.280.195.160; C14.280.238.070; C16.320.488.750
D002312	Cardiomyopathy, Hypertrophic	C14.280.238.100; C14.280.484.048.750.070.160
C563538	Cardiomyopathy, Dilated, 1s *(supp.)*
C564970	Myopathy, Hyaline Body, Autosomal Recessive *(supp.)*

ncRNA disease associations

Curated non-coding-RNA → disease associations (LncRNADisease, HMDD) — these are RNA-level associations for this gene, not the positional variant data omitted above.

3 ncRNA–disease associations:

Disease	Causal?	Validated by
Mucocutaneous Lymph Node Syndrome	No	qRT-PCR
Stomach Neoplasms	Yes	Western Blot, CCK8, qRT-PCR, Luciferase Report Assay, EdU Staining, Transwell Assay
Heart Failure	Yes	qRT-PCR

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 0 entries

CTD chemical–gene interactions

1 total (human), top 1 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Triclosan	decreases expression	1

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT00879060	Phase 4	COMPLETED	Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
NCT01721967	Phase 4	COMPLETED	Ranolazine for the Treatment of Chest Pain in HCM Patients
NCT02948998	Phase 4	UNKNOWN	Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy
NCT03249272	Phase 4	TERMINATED	Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
NCT04133532	Phase 4	COMPLETED	Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy
NCT06401343	Phase 4	UNKNOWN	Use of SGLT2i in noHCM With HFpEF
NCT07103655	Phase 4	ENROLLING_BY_INVITATION	The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
NCT07600177	Phase 4	RECRUITING	Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT07807384	Phase 4	NOT_YET_RECRUITING	Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT00348530	Phase 4	UNKNOWN	Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy
NCT00371891	Phase 4	COMPLETED	Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)
NCT00401856	Phase 4	COMPLETED	CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone
NCT00559338	Phase 4	COMPLETED	Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department
NCT00606775	Phase 4	UNKNOWN	The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy
NCT00658203	Phase 4	COMPLETED	Clinical Evaluation on Advanced Resynchronization
NCT00701220	Phase 4	COMPLETED	Statin Therapy for Ischemic and Nonischemic Cardiomyopathy
NCT00800761	Phase 4	COMPLETED	Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major
NCT00806390	Phase 4	TERMINATED	Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol
NCT01006473	Phase 4	COMPLETED	Exercise Training in Chagas Cardiomyopathy
NCT01261065	Phase 4	COMPLETED	Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure
NCT01345188	Phase 4	COMPLETED	Ranolazine in Ischemic Cardiomyopathy
NCT01868841	Phase 4	COMPLETED	123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System
NCT02640846	Phase 4	UNKNOWN	Effects of Levosimendan, Milrinone and Norepinephrine on Left and Right Ventricular Function in Septic Shock
NCT03228823	Phase 4	UNKNOWN	Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)
NCT04323852	Phase 4	COMPLETED	Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery?
NCT05034432	Phase 4	RECRUITING	The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients
NCT05371496	Phase 4	COMPLETED	Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
NCT05718128	Phase 4	RECRUITING	Clinical Study of Endocardial Myocardial Biopsy
NCT06964464	Phase 4	RECRUITING	Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
NCT00317967	Phase 3	COMPLETED	Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart
NCT00698074	Phase 3	UNKNOWN	Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy
NCT00821353	Phase 3	COMPLETED	Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy
NCT02431221	Phase 3	WITHDRAWN	Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure
NCT03470545	Phase 3	COMPLETED	Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT05174416	Phase 3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
NCT05182658	Phase 3	ACTIVE_NOT_RECRUITING	Empagliflozin in Hypertrophic Cardiomyopathy
NCT05186818	Phase 3	COMPLETED	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
NCT05767346	Phase 3	COMPLETED	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT06116968	Phase 3	COMPLETED	An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
NCT06873828	Phase 3	NOT_YET_RECRUITING	Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
NCT07021976	Phase 3	ACTIVE_NOT_RECRUITING	A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT07023341	Phase 3	ACTIVE_NOT_RECRUITING	A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT07202897	Phase 3	RECRUITING	LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
NCT00170183	Phase 3	COMPLETED	Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure
NCT00270387	Phase 3	COMPLETED	A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy
NCT00321295	Phase 3	COMPLETED	Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery
NCT00483197	Phase 3	UNKNOWN	VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial
NCT00490321	Phase 3	UNKNOWN	VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy
NCT00626028	Phase 3	COMPLETED	Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
NCT01013714	Phase 3	UNKNOWN	Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias
NCT01217827	Phase 3	COMPLETED	Implantable Cardioverter-Defibrillator Use in the VA System
NCT01648634	Phase 3	COMPLETED	Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy
NCT02924285	Phase 3	COMPLETED	Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease
NCT03860935	Phase 3	COMPLETED	Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
NCT04166331	Phase 3	COMPLETED	Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion
NCT05175066	Phase 3	COMPLETED	Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity
NCT05237323	Phase 3	COMPLETED	Micophenolate Mofetil Versus Azathioprine in Myocarditis
NCT06158698	Phase 3	RECRUITING	CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
NCT06563895	Phase 3	RECRUITING	Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06846086	Phase 3	RECRUITING	Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy